Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.097
  • Today's Change-0.002 / -2.02%
  • Shares traded493.75k
  • 1 Year change-73.78%
  • Beta0.9351
Data delayed at least 20 minutes, as of Jun 14 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.

  • Revenue in AUD (TTM)10.63m
  • Net income in AUD-8.40m
  • Incorporated1997
  • Employees50.00
  • Location
    Starpharma Holdings Ltd4-6 Southampton Crescent, AbbotsfordMELBOURNE 3067AustraliaAUS
  • Phone+61 38532-2700
  • Fax+61 39510-5955
  • Websitehttps://www.starpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acrux Ltd14.46m-709.00k22.39m43.00--3.96--1.55-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
BPH Energy Ltd345.67k894.65k22.95m2.00k20.410.9868--66.400.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
LBT Innovations Limited2.00m-21.38m24.14m17.00--8.88--12.04-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
BCAL Diagnostics Ltd3.67m-5.00m33.00m----4.35--8.98-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
Syntara Ltd9.83m-14.26m34.63m107.00--3.84--3.52-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Prescient Therapeutics Ltd697.94k-7.74m34.63m3.00--1.53--49.62-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Little Green Pharma Ltd25.63m-8.15m34.70m----0.4467--1.35-0.0272-0.02720.08560.25740.27721.0512.29---8.82---9.74--53.18---31.81--1.39-18.900.0624--29.07--4.72------
Starpharma Holdings Ltd10.63m-8.40m39.97m50.00--1.16--3.76-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Biotron Ltd1.65m-4.02m45.11m4.00--24.13--27.42-0.0045-0.00450.00180.00210.3587-------87.73-64.30-103.46-74.43-156.30-108.03-244.54-231.62----0.0148---8.16-2.48-25.59------
IDT Australia Limited10.36m-6.55m51.55m156.00--1.88--4.98-0.0215-0.02150.03410.06390.37412.393.51---23.64-9.87-26.41-11.5776.3884.42-63.19-24.942.81--0.0907---42.03-11.97-632.59---26.04--
Anteotech Ltd526.75k-11.46m51.83m40.00--9.71--98.40-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
LTR Pharma Ltd-100.00bn-100.00bn54.21m----17.09----------0.0451----------------------------0.00---100.00---41.65------
Cynata Therapeutics Ltd436.25k-13.65m55.69m0.00--4.54--127.65-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Data as of Jun 14 2024. Currency figures normalised to Starpharma Holdings Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

44.57%Per cent of shares held by top holders
HolderShares% Held
Allianz Global Investors Asia Pacific Ltd.as of 11 Aug 202348.48m11.77%
Allan Gray Australia Pty Ltd.as of 08 Sep 202347.82m11.61%
ICM Investment Management Ltd.as of 11 Aug 202321.36m5.18%
FIL Investment Advisors (UK) Ltd.as of 27 Sep 202320.29m4.93%
M&G Investment Management Ltd.as of 19 Oct 202318.16m4.41%
FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 202414.02m3.40%
Mirrabooka Investments Ltd. (Investment Management)as of 30 Jun 20238.70m2.11%
Norges Bank Investment Managementas of 31 Dec 20232.61m0.63%
Russell Investment Management Ltd.as of 28 Mar 20241.32m0.32%
DFA Australia Ltd.as of 30 Apr 2024902.45k0.22%
More ▼
Data from 31 Mar 2023 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.